- Malignant fibrous histiocytoma
Name = PAGENAME
DiseasesDB = 31471
OMIM = 8830/3
eMedicineSubj = radio
eMedicineTopic = 420
MeshID = D051677
Malignant fibrous histiocytoma (MFH) is a type of
cancerthat is the most common soft tissue sarcoma of late adult life, most commonly occurring between age 50-70. In rare cases MFH does occur in children, but it is usually in a less aggressive form. However, malignant tumors have occurred in children as young as 13. It occurs more often in caucasians than those of African or Asian descent. Its male:female predominance is 2:1.
It can be considered a
wastebasket diagnosisfor sarcomas that can not be more precisely categorized.cite web |url=http://library.med.utah.edu/WebPath/NEOHTML/NEOPL045.html |title=Neoplasia |format= |work= |accessdate=]
MFH occurs most commonly in the extremities and
retroperitoneum, but has been reported in many other sites (lung, head/neck, etc.). Development of metastasisdepends on the tumor's subtype. Metastasis occurs most frequently in the lung (90%), bone (8%) and liver (1%). In the extremities, it presents as a painless enlarging soft tissue mass. It can develop anywhere in the soft tissue, but also occurs at sites of previous radiation treatment, shrapnel implantation or next to prostheses.
It can be divided into two subtypes: "spindle cell" and "pleomorphic".cite journal |author=Scapolan M, Perin T, Wassermann B, "et al" |title=Expression profiles in malignant fibrous histiocytomas: Clues for differentiating 'spindle cell' and 'pleomorphic' subtypes |journal=Eur J Cancer |volume= |issue= |pages= |year=2007 |pmid=18054831 |doi=10.1016/j.ejca.2007.10.012 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(07)00797-6]
It can be detected by
magnetic resonance imaging(MRI), but a biopsy is required for definitive diagnosis.
Treatment consists of surgical excision(the extent of which ranges from tumor excision to limb amputation depending on the tumor) and in some cases
Prognosis depends on the primary tumor size and grade (aggressiveness). 5-year survival ranges from 35-60%.
* [http://www.liddyshriversarcomainitiative.org/Newsletters/V02N02/MFH/mfh.htm "Malignant Fibrous Histiocytoma (MFH)" by Carol Morris, MD]
Wikimedia Foundation. 2010.